Cristine Betzer

Cristine Betzer

Auto-generated profile, based on publicly available information

Cristine Betzer

Department of Biomedicine, Aarhus University

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
NLNikolai Lorenzen
Nikolai Lorenzen
SNSøren B. Nielsen
Søren B. Nielsen
YYYuichi Yoshimura
Yuichi Yoshimura
BVBrian S. Vad
Brian S. Vad
CACamilla Bertel Andersen
Camilla Bertel Andersen
DODaniel Otzen
Daniel Otzen
Oligomeric species of various proteins are linked to the pathogenesis of different neurodegenerative disorders. Consequently, there is intense focus on the discovery of novel inhibitors, e.g. small molecules and antibodies, to inhibit the formation and block the toxicity of oligomers. In Parkinson disease, the protein α-synuclein (αSN) forms cytotoxic oligomers. The flavonoid epigallocatechin gallate (EGCG) has previously been shown to redirect the aggregation of αSN monomers and remodel αSN amyloid fibrils into disordered oligomers. Here, we dissect EGCG's mechanism of action. EGCG inhibits the ability of preformed oligomers to permeabilize vesicles and induce cytotoxicity in a rat brain cell line. However, EGCG does not affect oligomer size distribution or secondary structure. Rather, EGCG immobilizes the C-terminal region and moderately reduces the degree of binding of oligomers to membranes. We interpret our data to mean that the oligomer acts by destabilizing the membrane rather than by direct pore formation. This suggests that reduction (but not complete abolition) of the membrane affinity of the oligomer is sufficient to prevent cytotoxicity.

24 July 2014 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
LZL Zondler
L Zondler
LML Miller-Fleming
L Miller-Fleming
MRMariaelena Repici
Mariaelena Repici
SGS Gonçalves
S Gonçalves
Sandra TenreiroSandra Tenreiro
Sandra Tenreiro
Tiago OuteiroTiago Outeiro
Tiago Outeiro
Parkinson’s disease (PD) is a devastating neurodegenerative disorder characterized by the loss of neurons in the substantia nigra pars compacta and the presence of Lewy bodies in surviving neurons. These intracellular protein inclusions are primarily composed of misfoldedα-synuclein (aSyn), which has also been genetically linked to familial and sporadic forms of PD. DJ-1 is a small ubiquitously expressed protein implicated in several pathways associated with PD pathogenesis. Although mutations in the gene encoding DJ-1 lead to familial early-onset PD, the exact mechanisms responsible for its role in PD pathogenesis are still elusive. Previous work has found that DJ-1 – which has protein chaperone-like activity – modulates aSyn aggregation. Here, we investigated possible physical interactions between aSyn and DJ-1 and any consequent functional and pathological relevance. We found that DJ-1 interacts directly with aSyn monomers and oligomersin vitro, and that this also occurs in living cells. Notably, several PD-causing mutations in DJ-1 constrain this interaction. In addition, we found that overexpression of DJ-1 reduces aSyn dimerization, whereas mutant forms of DJ-1 impair this process. Finally, we found that human DJ-1 as well as yeast orthologs of DJ-1 reversed aSyn-dependent cellular toxicity inSaccharomyces cerevisiae. Taken together, these data suggest that direct interactions between DJ-1 and aSyn constitute the basis for a neuroprotective mechanism and that familial mutations in DJ-1 may contribute to PD by disrupting these interactions.

29 March 2018 in EMBO Reports
Verified
Journal Article
Open access
PDF file
CBCristine Betzer
Cristine Betzer
LLLouise Berkhoudt Lassen
Louise Berkhoudt Lassen
Anders OlsenAnders Olsen
Anders Olsen
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
LRLasse Reimer
Lasse Reimer
PJPoul Henning Jensen
Poul Henning Jensen
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

26 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LLLouise Berkhoudt Lassen
Louise Berkhoudt Lassen
EGEmil Gregersen
Emil Gregersen
AIAnne Kathrine Isager
Anne Kathrine Isager
CBCristine Betzer
Cristine Betzer
RKRikke Hahn Kofoed
Rikke Hahn Kofoed
PJPoul Henning Jensen
Poul Henning Jensen
Soluble aggregates of α-synuclein, so-called oligomers, are hypothesized to act as neurotoxic species in Parkinson’s disease, Lewy body dementia and multiple systems atrophy, but specific tools to detect these aggregated species are only slowly appearing. We have developed an α-synuclein oligomer ELISA that allows us to detect and compare α-synuclein oligomer levels in different in vivo and in vitro experiments. The ELISA is based on commercially available antibodies and the epitope of the capture antibody MJF14-6-4-2 is folding- and aggregate-dependent and not present on monomers.

6 February 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CBCristine Betzer
Cristine Betzer
AMA. James Movius
A. James Movius
MSMin Shi
Min Shi
WGWei-Ping Gai
Wei-Ping Gai
JZJing Zhang
Jing Zhang
PJPoul Henning Jensen
Poul Henning Jensen
Monomeric α-synuclein (αSN) species are abundant in nerve terminals where they are hypothesized to play a physiological role related to synaptic vesicle turn-over. In Parkinson’s disease (PD) and dementia with Lewy body (DLB), αSN accumulates as aggregated soluble oligomers in terminals, axons and the somatodendritic compartment and insoluble filaments in Lewy inclusions and Lewy neurites. The autosomal dominant heritability associated to mutations in the αSN gene suggest a gain of function associated to aggregated αSN. We have conducted a proteomic screen to identify the αSN interactome in brain synaptosomes. Porcine brain synaptosomes were fractionated, solubilized in non-denaturing detergent and subjected to co-immunoprecipitation using purified recombinant human αSN monomers or oligomers as bait. The isolated αSN binding proteins were identified with LC-LTQ-orbitrap tandem mass spectrometry and quantified by peak area using Windows client application, Skyline Targeted Proteomic Environment. Data are available via ProteomeXchange with identifier PXD001462. To quantify the preferential binding an average fold increase was calculated by comparing binding to monomer and oligomer. We identified 10 proteins preferentially binding monomer, and 76 binding preferentially to oligomer and a group of 92 proteins not displaying any preferred conformation of αSN. The proteomic data were validated by immunoprecipitation in both human and porcine brain extracts using antibodies against monomer αSN interactors: Abl interactor 1, and myelin proteolipid protein, and oligomer interactors: glutamate decarboxylase 2, synapsin 1, glial fibrillary acidic protein, and VAMP-2. We demonstrate the existence of αSN conformation selective ligands and present lists of proteins, whose identity and functions will be useful for modeling normal and pathological αSN dependent processes.

19 December 2019 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
SESara Elfarrash
Sara Elfarrash
NJNanna Møller Jensen
Nanna Møller Jensen
Nelson FerreiraNelson Ferreira
Nelson Ferreira
CBCristine Betzer
Cristine Betzer
JTJervis Vermal Thevathasan
Jervis Vermal Thevathasan
PJPoul Henning Jensen
Poul Henning Jensen
Here we describe the use of an organotypic hippocampal slice model for studying α-synuclein aggregation and inter-neuronal spreading initiated by microinjection of pre-formed α-synuclein fibrils (PFFs). PFF injection at dentate gyrus (DG) templates the formation of endogenous α-synuclein aggregates in axons and cell bodies of this region that spread to CA3 and CA1 regions. Aggregates are insoluble and phosphorylated at serine-129, recapitulating Lewy pathology features found in Parkinson’s disease and other synucleinopathies. The model was found to favor anterograde spreading of the aggregates. Furthermore, it allowed development of slices expressing only serine-129 phosphorylation-deficient human α-synuclein (S129G) using an adeno-associated viral (AAV) vector in α-synuclein knockout slices. The processes of aggregation and spreading of α-synuclein were thereby shown to be independent of phosphorylation at serine-129. We provide methods and highlight crucial steps for PFF microinjection and characterization of aggregate formation and spreading. Slices derived from genetically engineered mice or manipulated using viral vectors allow testing of hypotheses on mechanisms involved in the formation of α-synuclein aggregates and their prion-like spreading.